Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition [PDF]
Pharmacogenomics and Personalized Medicine, 2014 M William Audeh Division of Medical Oncology, Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA Abstract: Inhibitors of the poly(adenosine triphosphate-ribose) polymerase (PARP)-1 enzyme induce synthetic lethality in ...
Audeh MW
doaj +2 more sources
Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report [PDF]
Journal of International Medical Research, 2021 exaly +2 more sources
Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation [PDF]
Journal of Immunotherapy and Precision Oncology, 2023 Poly (adenosine diphosphate-ribose) polymerase inhibitors (PARP)i are emerging as standard oncology treatments in various tumor types. The indications will expand as PARPi are being investigated in various breast cancer subtypes.
Anca Chelariu-Raicu +10 more
doaj +1 more source
Inhibition of poly(adenosine diphosphate-ribose) polymerase attenuates ventilator-induced lung injury [PDF]
, 2008 BACKGROUND: Mechanical ventilation can induce organ injury associated with overwhelming inflammatory responses. Excessive activation of poly(adenosine diphosphate-ribose) polymerase enzyme after massive DNA damage may aggravate inflammatory responses ...
de Corte, F. +19 more
core +3 more sources
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity
mAbs, 2022 Cluster of differentiation 38 (CD38) is an ecto-enzyme expressed primarily on immune cells that metabolizes nicotinamide adenine dinucleotide (NAD+) to adenosine diphosphate ribose or cyclic ADP-ribose and nicotinamide.
Harshad S. Ugamraj +19 more
doaj +1 more source
PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages
Pathogens, 2023 Aberrant adenosine diphosphate-ribose (ADP)-ribosylation of proteins and nucleic acids is associated with multiple disease processes such as infections and chronic inflammatory diseases. The poly(ADP-ribose) polymerase (PARP)/ADP-ribosyltransferase (ART)
Diego V. Santinelli-Pestana +3 more
doaj +1 more source
First-Line PARP Inhibitors—Emerging Side Effects Require Caution: A Case of PARPi-Induced Pneumonitis [PDF]
Journal of Immunotherapy and Precision Oncology, 2021 Niraparib, an inhibitor of poly(adenosine diphosphate [ADP]-ribose) 1 and 2, has been shown to improve progression free survival in patients when used as maintenance treatment after first-line platinum-based chemotherapy in advanced stage (III to IV ...
Alistair McLaren +3 more
doaj +1 more source
Structure/function analysis of PARP-1 in oxidative and nitrosative stress-induced monomeric ADPR formation. [PDF]
PLoS ONE, 2009 Poly adenosine diphosphate-ribose polymerase-1 (PARP-1) is a multifunctional enzyme that is involved in two major cellular responses to oxidative and nitrosative (O/N) stress: detection and response to DNA damage via formation of protein-bound poly ...
Ben Buelow +3 more
doaj +1 more source
The Critical Role of PARPs in Regulating Innate Immune Responses
Frontiers in Immunology, 2021 Poly (adenosine diphosphate-ribose) polymerases (PARPs) are a family of proteins responsible for transferring ADP-ribose groups to target proteins to initiate the ADP-ribosylation, a highly conserved and fundamental post-translational modification in all
Huifang Zhu +4 more
doaj +1 more source
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Case Reports in Oncology, 2023 Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor.
Mana Sekine +3 more
doaj +1 more source